Loading...
A048530 logo

iNtRON Biotechnology, Inc.KOSDAQ:A048530 Stock Report

Market Cap ₩99.4b
Share Price
₩3.15k
₩558.61
463.0% overvalued intrinsic discount
1Y-23.1%
7D-0.5%
1D
Portfolio Value
​
View

iNtRON Biotechnology, Inc.

KOSDAQ:A048530 Stock Report

Market Cap: ₩99.4b

iNtRON Biotechnology (A048530) Stock Overview

Engages in the development of novel biopharmaceutical drugs in South Korea. More details

A048530 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends1/6

Risk Analysis

Earnings have declined by 61.9% per year over past 5 years

Dividend of 3.18% is not well covered by earnings or free cash flows

Volatile share price over the past 3 months compared to the KR market

Does not have a meaningful market cap (₩99B)

+ 1 more risk

A048530 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

iNtRON Biotechnology, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for iNtRON Biotechnology
Historical stock prices
Current Share Price₩3,145.00
52 Week High₩7,010.00
52 Week Low₩2,895.00
Beta0.15
1 Month Change-17.24%
3 Month Change-13.60%
1 Year Change-23.11%
3 Year Change-58.62%
5 Year Change-86.33%
Change since IPO-21.38%

Recent News & Updates

Analysis Article • Nov 08

iNtRON Biotechnology (KOSDAQ:048530) Is Due To Pay A Dividend Of ₩100.00

iNtRON Biotechnology, Inc.'s ( KOSDAQ:048530 ) investors are due to receive a payment of ₩100.00 per share on 15th of...

Recent updates

Analysis Article • Nov 08

iNtRON Biotechnology (KOSDAQ:048530) Is Due To Pay A Dividend Of ₩100.00

iNtRON Biotechnology, Inc.'s ( KOSDAQ:048530 ) investors are due to receive a payment of ₩100.00 per share on 15th of...
Analysis Article • Nov 03

Is iNtRON Biotechnology (KOSDAQ:048530) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Nov 15

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • May 03

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Mar 24

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

iNtRON Biotechnology, Inc. ( KOSDAQ:048530 ) recently released a strong earnings report, and the market responded by...
Analysis Article • Feb 28

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

It might be of some concern to shareholders to see the iNtRON Biotechnology, Inc. ( KOSDAQ:048530 ) share price down...
Analysis Article • Jan 31

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

Most readers would already be aware that iNtRON Biotechnology's (KOSDAQ:048530) stock increased significantly by 69...
Analysis Article • Jan 05

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Dec 10

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

iNtRON Biotechnology, Inc. ( KOSDAQ:048530 ) shares have had a really impressive month, gaining 26% after a shaky...
Analysis Article • Nov 26

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

iNtRON Biotechnology, Inc. (KOSDAQ:048530) shareholders should be happy to see the share price up 13% in the last...

Shareholder Returns

A048530KR BiotechsKR Market
7D-0.5%0.3%4.6%
1Y-23.1%33.0%186.6%

Return vs Industry: A048530 underperformed the KR Biotechs industry which returned 33.1% over the past year.

Return vs Market: A048530 underperformed the KR Market which returned 186.6% over the past year.

Price Volatility

Is A048530's price volatile compared to industry and market?
A048530 volatility
A048530 Average Weekly Movement16.2%
Biotechs Industry Average Movement11.5%
Market Average Movement9.4%
10% most volatile stocks in KR Market16.6%
10% least volatile stocks in KR Market4.9%

Stable Share Price: A048530's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A048530's weekly volatility has increased from 10% to 16% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199973Alek Yoonwww.intron.co.kr

iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.

iNtRON Biotechnology, Inc. Fundamentals Summary

How do iNtRON Biotechnology's earnings and revenue compare to its market cap?
A048530 fundamental statistics
Market cap₩99.43b
Earnings (TTM)-₩8.96b
Revenue (TTM)₩5.74b
17.3x
P/S Ratio
-11.1x
P/E Ratio

Is A048530 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A048530 income statement (TTM)
Revenue₩5.74b
Cost of Revenue₩2.70b
Gross Profit₩3.04b
Other Expenses₩12.00b
Earnings-₩8.96b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-283.37
Gross Margin53.05%
Net Profit Margin-156.06%
Debt/Equity Ratio4.3%

How did A048530 perform over the long term?

See historical performance and comparison

Dividends

3.2%
Current Dividend Yield
-51%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 10:51
End of Day Share Price 2026/05/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

iNtRON Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sangsoo KimGoldman Sachs